text:
Home History What event lead to the first shots being fired at the battle of lexington and concord?
What event lead to the first shots being fired at the battle of lexington and concord?
History SmithjirrahOctober 23, 202112 Comments
What event lead to the first shots being fired at the battle of lexington and concord? a. the attempt by the british to seize colonial military stores b. the rejection of the olive branch petition by king george lll c. the writing and public reading of the declaration of independence d. the blockage of the port of boston by the. ritual navy
Smithjirrah
Why did craft guilds form in the middle ages? to eliminate the growing number of merchant guilds in european towns to address
Yoyo2697October 23, 20217 Comments
3. I am the belief that God gave the United States the right to spread across the continent.bringing freedom and liberty to everyone
AuraziabagleyOctober 23, 20212 Comments
The harlem hellfighters1- musicians during the harlem renaissance 2- social activists that led into
EmileehoganOctober 23, 202110 Comments
:( which of the following is a true statement about early american cultures? a.) early american cultures
Alyxkellar06October 23, 20219 Comments
Nationalism is an intense loyalty to ones a. family b. race c. religon d. country
List and explain three reasons for the industrial revolution beginning in britain
IneedtopeebeforethecOctober 23, 20213 Comments
kcnawlay170 says:
On the night of April 18, 1775, hundreds of British troops marched from Boston to nearby Concord in order to seize an arms cache. Paul Revere and other riders sounded the alarm, and colonial militiamen began mobilizing to intercept the Redcoat column.
Iagree ☝ with that dude
chickenhead123 says:
In 1861, many did not believe the Civil War would last long; however, FIGHTING LASTED FOUR YEARS!
AnActualTrashcan says:
The attempt by British General Have to seize Colonial military stores.
epmeche05 says:
In 1861, many did not believe the Civil War would last long; however, the fighting lasted four years.
The Civil war was the deadliest war in the United States of America, the president at the time Abraham Lincoln wanted to abolish slavery and the fight between the Union and The Confederate States became brutal, this was a very long war were many died from little young to elderly fought. In this line, the word "however" is an expression of contrast in the ideas, which makes "the fight lasted four years" the best answer from being opposite to the first sentence that says people did not believe it would last long
tburlew01 says:
they were on bridge someone shoot and war
pleasedontspamme says:
The actions that resulted from the Mecklenburg Resolves were the following: The provincial assembly gained government power; Laws passed by the British government were annulled.
The Mecklenburg Resolves are a set of anti-British resolutions that were entered into agreement by local authorities and influential citizens in Mecklenburg County (Charlotte), North Carolina in 1775. It is said to predate the actual and official Declaration of Independence on July 4th, 1776. There is controversy surrounding the supposed existence of a "Mecklenburg Declaration of Independence" even more radical or declaratory than the Resolves. It is not known who signed the Resolves, but they were published by local papers in North Carolina and South Carolina in 1775. It is significant because it shows there was a grassroots push to independence as other cities and towns in North Carolina followed suit like Wilmington and Fayetteville in giving the Provincial Congress power and vacating or annulling British laws.
madisontrosclair2 says:
B. British troops and minutemen fired their weapons at each other.
On Lexington Green, in 1775 the first shots of the American Revolutionary War were fired and the battles of Lexington and Concord began.
They marked the outbreak of the armed conflict between the Kingdom of Great Britain and the American thirteen colonies. The first shots were fired by the British forces and the militiamen responded, casualties were on both sides.
I hope this answer helps you.
pierrezonra says:
Answers are:-
1. The provincial assembly gained government power.
3. Laws passed by the British government were annulled.
The Mecklenburg Resolves also known as Charlotte Town Resolves are the list of anti-British statements that were agreed by the local authorities and influential citizens in Charlotte in 1775. The Mecklenburg Resolves is believed to be the basis for the unproven "Mecklenburg Declaration of Independence" because there is a controversy surrounding this. It is not clear who signed this Resolves, but newspapers published the same. People wanted independence from the British laws and cancel them. They wanted to give power to Provincial Congress.
Options 1 and 3 clearly indicates these points. Other options are incorrect.
rainbowboy6055 says:
B) The British and the minutemen fired on one another, starting the revolution.
anonymous174 says:
He still sleeping alone in the hospital after he was exposed in the fired he was shoted in the chest .
a standing committee
[tex]Which type of congregational committee does the passage most likely describe?[/tex]


Welcome To The Archive for "Captain Marvel"!
Danvers has been featured in other Marvel licensed products including video games, animated television series, and merchandise such as trading cards. On March 8, 2019, Marvel Studios is scheduled to release a live-action film featuring Danvers, titled Captain Marvel and starring Brie Larson. Larson is also scheduled to reprise the role in Avengers: Endgame.


All anime and manga enthusiasts in 6th to 8th grade are welcome to join this free club at the Northeast Library. Enjoy popcorn/snacks, streaming anime (no commercials!) and crafts (optional) at every meeting. You are also welcome to bring ANY art/manga/fanart/fanfic you've been working on outside of the club to present and/or work on at the library. No registration required. 6th, 7th and 8th graders only, please.


text:
DA, New Orleans City Council at odds over controversial practice involving crime victims
Updated: 10:21 AM CST Feb 8, 2019
Travers Mackel
WEBVTT >> -- TRAVERS: LEUNG CANNIZARO DEFINED. >> TODAY'S CITY COUNCIL MEETING PRODUCED A PREDICTABLE AND TRANSPARENT POLITICAL ATTACK UPON THIS OFFICE. TRAVERS: REFUSING TO GIVE UP ON A CONTROVERSIAL PRACTICE WHERE HIS OFFICE JAILS VICTIMS OF VIOLENT CRIMES IN ORDER TO FORCE THEM TO TESTIFY AGAINST THEIR ALLEGED ASSAILANTS. CANNIZZARO SAYS HE ONLY DOES IT IN EXTREME CASES, WHEN A VICTIM INITIALLY AGREES TO TESTIFY AND THEN BACKS OUT. >> IN EACH INSTANCE, THE WITNESS TESTIMONY WAS DEEMED CRITICAL NOT BY ME, BUT BY THE JUDGE TO PREVENTING A DANGEROUS OFFENDER FROM WALKING FREE TO VICTIMIZE OTHERS. TRAVERS: THE CITY COUNCIL WANTS IT TO STOP. >> ITS MISOGYNISTIC, IT IS BARBARIC, AND IT IS DESPICABLE. TRAVERS: COUNCIL PRESIDENT JAYSON WILLIAMS IS A DEFENSE ATTORNEY AND PLANS ON RUNNING FOR DA IN 2020. HE AND HIS COLLEAGUES VOTED 7-0, PASSING A RESOLUTION ASKING THE DA TO STOP THE PRACTICE. >> I BELIEVE THIS IS A HORRIFIC ABUSE OF THE DA'S POWER. TRAVERS: THE NONPROFIT GROUP COURT WATCH NOLA SAYS THE DA HAS JAILED 10 PEOPLE IN TWO YEARS IN ORDER TO GET THEM TO TESTIFY. THE ACLU ALSO CITED WITH THE COUNCIL.
The City Council in New Orleans took a united stand against the city's top prosecutor and a practice they called "barbaric."It all centers on jailing victims of violent crime.The council voted 7-0 on a resolution, formally asking Orleans Parish District Attorney Leon Cannizzaro to stop a little-used practice of jailing victims and witnesses of violent crimes in order to get them to testify."Today's City Council meeting produced a transparent attack on this office," said Cannizzaro.The nonprofit group CourtWatch NOLA said the district attorney has done it about 10 times over the last two years in extreme circumstances when a victim is the only witness and refuses to testify against a criminal suspect.The council is also asking state lawmakers to pass a state law banning the practice.A New Orleans-based state senator has agreed to carry that legislation, as the issue is only a problem in New Orleans.The council said it's an embarrassment for the city that it keeps happening."The idea that a top prosecutor will jail victims of rapes and domestic violence is misogynistic, barbaric and despicable," said Council member Jason Williams, who's also a criminal defense attorney and an announced candidate for DA in 2020.Cannizzaro fired back Thursday afternoon, saying the practice, while unconventional, saves lives."A material witness warrant is never the intention of any DA or defense attorney, but sometimes we have to make tough choices in service of justice and the truth."The Louisiana American Civil Liberties Union sides with the council on this issue.The resolution is not legally binding and does not legally stop Cannizzaro from acting. It's only a formal request that he stop the practice.In a written statement, CourtWatch NOLA says:"Court Watch NOLA is a public accountability group comprised of New Orleanians from all walks of life. It's objective is to inspire public trust in the criminal justice system. Cannizzaro's remarks and actions on this issue suggest an unwillingness to be accountable to the public he is sworn to serve. Bullying does not work with crime victims or watchdog groups."Keep up with local news, weather and current events with the WDSU app here. Sign up for our email newsletters to get breaking news right in your inbox. Click here to sign up!
The City Council in New Orleans took a united stand against the city's top prosecutor and a practice they called "barbaric."
It all centers on jailing victims of violent crime.
The council voted 7-0 on a resolution, formally asking Orleans Parish District Attorney Leon Cannizzaro to stop a little-used practice of jailing victims and witnesses of violent crimes in order to get them to testify.
"Today's City Council meeting produced a transparent attack on this office," said Cannizzaro.
The nonprofit group CourtWatch NOLA said the district attorney has done it about 10 times over the last two years in extreme circumstances when a victim is the only witness and refuses to testify against a criminal suspect.
The council is also asking state lawmakers to pass a state law banning the practice.
A New Orleans-based state senator has agreed to carry that legislation, as the issue is only a problem in New Orleans.
The council said it's an embarrassment for the city that it keeps happening.
"The idea that a top prosecutor will jail victims of rapes and domestic violence is misogynistic, barbaric and despicable," said Council member Jason Williams, who's also a criminal defense attorney and an announced candidate for DA in 2020.
Cannizzaro fired back Thursday afternoon, saying the practice, while unconventional, saves lives.
"A material witness warrant is never the intention of any DA or defense attorney, but sometimes we have to make tough choices in service of justice and the truth."
The Louisiana American Civil Liberties Union sides with the council on this issue.
The resolution is not legally binding and does not legally stop Cannizzaro from acting. It's only a formal request that he stop the practice.
In a written statement, CourtWatch NOLA says:
"Court Watch NOLA is a public accountability group comprised of New Orleanians from all walks of life. It's objective is to inspire public trust in the criminal justice system. Cannizzaro's remarks and actions on this issue suggest an unwillingness to be accountable to the public he is sworn to serve. Bullying does not work with crime victims or watchdog groups."
Keep up with local news, weather and current events with the WDSU app here. Sign up for our email newsletters to get breaking news right in your inbox. Click here to sign up!

redpajama_set_name: RedPajamaCommonCrawl


text:
Home / Student Jobs / Onyx Updates, January 6, 2023
Your Onyx Newsletter for January 6, 2023
New Grad, Advisor/Senior Advisor, Valuation Governance (Real Estate) - PSP
Andy Francis in Job Postings 22 hours ago
ABOUT US We're one of Canada's largest pension investment managers, with CAD$230.5 billion of net assets as at March 31, 2022. We invest funds for the pension plans of the federal public service, the Canadian Forces, the Royal Canadian Mounted Police and the Reserve Force. Headquartered in Ottawa, PSP Investments has its principal business ...
New . . .


Tumor development and progression is the consequence of genetic as well as epigenetic alterations of the cell. As part of the epigenetic regulatory system, histone acetyltransferases (HATs) and deacetylases (HDACs) drive the modification of histone as well as non-histone proteins. Derailed acetylation-mediated gene expression in cancer due to a delicate imbalance in HDAC expression can be reversed by histone deacetylase inhibitors (HDACi). Histone deacetylase inhibitors have far-reaching anticancer activities that include the induction of cell cycle arrest, the inhibition of angiogenesis, immunomodulatory responses, the inhibition of stress responses, increased generation of oxidative stress, activation of apoptosis, autophagy eliciting cell death, and even the regulation of non-coding RNA expression in malignant tumor cells. However, it remains an ongoing issue how tumor cells determine to respond to HDACi treatment by preferentially undergoing apoptosis or autophagy. In this review, we summarize HDACi-mediated mechanisms of action, particularly with respect to the induction of cell death. There is a keen interest in assessing suitable molecular factors allowing a prognosis of HDACi-mediated treatment. Addressing the results of our recent study, we highlight the role of p53 as a molecular switch driving HDACi-mediated cellular responses towards one of both types of cell death. These findings underline the importance to determine the mutational status of p53 for an effective outcome in HDACi-mediated tumor therapy.


text:
Home Features Gauging Big Pharma's Performance and OutlookByPatricia Van Arnum
Gauging Big Pharma's Performance and Outlook
Amgen Advances Biosimilar Adalimumab
Earnings season has begun with many of the pharmaceutical majors reporting 2014 results. So how did companies fare and what is their outlook for 2015? DCAT Value Chain Insights (VCI) examines 2014 performance and what lies ahead.
Many of the pharmaceutical majors released their earnings last week, offering not only highlights of their financial performance but also insight into the strategies that will shape their near-term focus. So what were the highlights for top-selling drugs, pipeline candidates, and other initiatives? DCAT Value Chain Insights (VCI) takes an inside look.
A roundup of activity
Pfizer. In 2014, Pfizer reported a 9% decline in revenues year over year to $49.6 billion. At the beginning of fiscal year 2014, the company began managing its commercial operations through a new global commercial structure consisting of two distinct businesses: an Innovative Products business and an Established Products business. The Innovative Products business is composed of two operating segments: the Global Innovative Pharmaceutical segment (GIP) and the Global Vaccines, Oncology and Consumer Healthcare segment (VOC). The Established Products business consists of the Global Established Pharmaceutical segment (GEP). The company's GEP segment reported 2014 revenues of $25.149 billion, down 9% year over year, and a 3% decline in GIP revenues to $13.861 billion. Revenues in its Global Vaccines business were up 13% to $4.480 billion. Revenues in its Consumer Healthcare business was were up 3% to$3.466 billion, and revenues in its Global Oncology business were up 12% to $2.218 billion.
In commenting on the results, Ian Read, chairman and chief executive officer (CEO) of Pfizer said: "During 2014, despite significant continued revenue headwinds from product losses of exclusivity and co-promote expiries, we were able to deliver modest adjusted diluted EPS [earnings per share] growth.This was achieved through a combination of incremental revenue generation from key inline products and recent product launches, responsible expense management as well as supportive capital allocation."
Going forward in 2015, a key development for Pfizer is the recent approval by the US Food and Drug Administration (FDA) for the company's new molecular entity, Ibrance (palbociclib), a small molecule to treat advanced (metastatic) breast cancer. In addition to this development, Read said the company expects strong growth in emerging markets (revenues in emerging markets increased 7% operationally in 2014) and from recent product launches in developed markets, including: Eliquis (apixaban), an anticoagulant; Xeljanz (tofacitinib), a drug to treat rheumatoid arthritis; the vaccine, Prevnar 13, in adults; and Nexium 24HR, an over-the-counter version of the gastrointestinal drug, esomeprazole. Pfizer announced in January 2015 that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending that the indication for Prevenar 13 be expanded to include the prevention of pneumonia caused by the 13 pneumococcal serotypes in the vaccine in adults 18 years and older. Prevenar 13 is currently approved in Europe for the prevention of invasive pneumococcal disease in the same population.
Pfizer plans to begin 20 registrational studies during the coming four years with candidates with target indications that have significant unmet need. One key area is in immunotherapies. In November 2014, Pfizer entered into an agreement with Merck KGaA to jointly develop and commercialize MSB0010718C (proposed international non-proprietary name is avelumab), an investigational anti-PD-L1 antibody currently in development as a potential treatment for multiple types of cancer. Pfizer and Merck KGaA will explore the therapeutic potential of this anti-PD-L1 antibody as a single agent as well as in various combinations with Pfizer's and Merck KGaA's portfolio of approved and investigational oncology therapies. Both companies will collaborate on up to 20 high priority immuno-oncology clinical development programs expected to commence in 2015.These clinical development programs include up to six trials (Phase II or III) that In addition, separate from the PD-L1 programs, Pfizer and Merck KGaA will also combine resources and expertise to advance Pfizer's anti-PD-1 antibody into Phase I trials. The parties have also agreed to co-promote Pfizer's Xalkori (crizotinib), a drug to treat non-small-cell lung cancer, in the US and several other key markets. Under the agreement, Merck KGaA received an upfront payment of $850 million and is eligible to receive regulatory and commercial milestone payments of up to approximately $2 billion. Both companies will jointly fund all development and commercialization costs, and split equally any profits generated from selling any anti- PD-L1 or anti-PD-1 products from this collaboration.
Novartis. In 2014, Novartis' overall net sales increased 1% (+3% constant currency (cc)) to $58.0 billion. Growth products contributed $18.6 billion or 32% of the company's net sales, up 18% (in US dollars) over 2013. Loss of exclusivity, including for its hypertensive drug, Diovan (valsartan), impacted sales by approximately $2.4 billion. The company's pharmaceuticals division delivered net sales of $31.8 billion (-1%, +1% cc) for the full year 2014, driven by volume growth (+7 percentage points) and pricing (+1 percentage points), offset by the impact of generic competition (-7 percentage points). Growth products continued to drive performance and generate $13.7 billion of division net sales, up 17% (cc) over the previous year. From a divisional perspective, the company expects net sales performance (cc) in 2015 to be in the mid-single digit growth for its pharmaceutical division, mid- to high-single digit growth for Alcon, its eye division, and mid-single digit growth for Sandoz, its generics business.
Novartis is also proceeding with two important deals announced in 2014. On January 1, 2015, Novartis announced that it completed the divestment of its Animal Health Division to Eli Lilly for approximately $5.4 billion. This divestment is part of a set of transactions announced in April 2014 to focus Novartis on three leading businesses: innovative pharmaceuticals, eye care, and generics. That deal was concurrent to a three-part transaction with GlaxoSmithKline (GSK), which is expected to be completed in the first half of 2015. Under the deal, Novartis is divesting its vaccines business (excluding influenza vaccines) to GSK, creating a consumer healthcare joint venture with GSK, and acquiring GSK's marketed oncology portfolio, related R&D activities and rights to two pipeline AKT inhibitors.
Novartis also is proceeding with ongoing productivity initiatives related to procurement and resource allocation across the portfolio as well as in R&D, manufacturing, and supporting infrastructure. Novartis Business Services (NBS) was launched in July 2014, and at the end of fourth quarter of 2014, it had over 7,500 associates. The organizational structure was established and the financial systems were in place as of January 2015, making NBS fully operational as a shared services organization. NBS is designed to enhance profitability by harmonizing services at better price across the group and divisions.
In terms of key recent drug approvals and pipeline developments, in January 2015, the company's Cosentyx (secukinumab) received regulatory approval in the US and European Union (EU) for psoriasis, following the December 2014 approval in Japan in psoriasis vulgaris and psoriatic arthritis. In January 2015, the FDA Oncologic Drugs Advisory Committee recommended approval of Sandoz's investigational biosimilar filgrastim in the US for use in all indications included in the reference product's (Neupogen) label. Some key regulatory filings include are US and EU filings for LCZ696 as a treatment for patients with heart failure with reduced ejection fraction, and a submission to the FDA for QVA149 and NVA237 for the long-term maintenance treatment of chronic obstructive pulmonary disease.
Roche. Roche reported group sales of CHF 47.5 billion ($41. 4 billion) in 2014. Growth in pharmaceuticals was driven by medicines for HER2-positive breast cancer (+ 20%), as well as the cancer drug Avastin (bevacizumab) (+ 6%). New products, Perjeta (pertuzumab) and the antibody drug conjugate, Kadcyla (trastuzumab emtansine), both for treating HER2-positive breast cancer, made a contribution to growth, which offset declining sales of the cancer drug, Xeloda (capecitabine), which now faces generic competition. The company reported strong demand for immunology medicines, notably Actemra/RoActemra (tocilizumab) (+ 23%) for rheumatoid arthritis and Xolair (omalizuma) (+2 5%) for treating chronic hives and allergic asthma. Sales of the antiviral medicine, Tamiflu (oseltamivir) (+ 54%), increased considerably late in 2014 as a result of the US flu epidemic. In 2015, Roche expects overall sales to grow in the low- to mid-single digits at constant exchange rate.
In terms of key products' progress, in 2014, two new indications were approved for the cancer medicine, Avastin: platinum-resistant ovarian cancer and cervical cancer. Gazyvaro (obinutuzumab), a glycoengineered anti-CD20 monoclonal antibody, was approved for the treatment of chronic lymphocytic leukemia in Europe. Esbriet, a recently acquired idiopathic pulmonary fibrosis (IPF) medicine, was granted FDA Breakthrough Therapy Designation in July 2014 and subsequently launched in October 2014 in the US following regulatoryapproval. Esbriet was granted marketing authorization in the European Union (EU) in 2011 for the treatment of adults with mild to moderate IPF in all 28 EU member countries and has since been approved in Norway, Iceland, Canada. Also in 2014, the FDA granted Breakthrough Therapy Designation for Lucentis (ranibizumab) in diabetic retinopathy and for a new cancer immunotherapy compound, an anti-PDL1, in bladder cancer. Also, over the last ten months, Roche has made 10 targeted acquisitions to complement its current product portfolio overall, including InterMune, the developer of Esbriet (pirfenidone), and Seragon Pharmaceuticals, which is researching treatments for hormone receptor-positive breast cancer.
Johnson & Johnson. Johnson & Johnson reported worldwide sales for the full-year 2014 of $74.3 billion, an increase of 4.2% versus 2013. Operational results increased 6.1%, and the negative impact of currency was 1.9%. Domestic sales increased 9.0%. International sales increased 0.4%, reflecting operational growth of 3.7% and a negative currency impact of 3.3%. Worldwide pharmaceutical sales were $32.3 billion for the full-year 2014, an increase of 14.9% versus the prior year with operational growth of 16.5% and a negative impact from currency of 1.6%. Domestic sales increased 25.0%; international sales increased 5.0%, which reflected an operational increase of 8.3% and a negative currency impact of 3.3%.
The strong sales results were driven by new products and the strength of core products. New products included Olysio/Sovriad (simeprevir) for combination treatment of chronic hepatitis C in adult patients; Xarelto (rivaroxaban), an oral anticoagulant; Zytiga (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer; Invokana (canagliflozin), for the treatment of adults with Type 2 diabetes; and Imbruvica (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, or blood cancers. Additional contributors to operational sales growth were Stelara (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis; Invega/Sustenna/Xeplion(paliperidone palmitate), a once-monthly, long-acting, injectable atypical antipsychotic for the treatment of schizophrenia in adults; Simponi/Simponi Aria (golimumab) and Remicade (infliximab), biologics approved for the treatment of a number of immune-mediated inflammatory diseases.
In the fourth quarter of 2014, the company submitted two new drug applications (NDAs) to the FDA for regulatory approval. These included an NDA for three-month atypical antipsychotic paliperidone palmitate as a treatment for schizophrenia in adults as well as an NDA for Yondelis (trabectedin) for the treatment of patients with advanced soft tissue sarcoma, including liposarcoma and leiomyosarcoma subtypes, who have received prior chemotherapy including an anthracycline. Also, a supplemental NDA was submitted to the FDA and a Type II variation application was submitted to the EMA for an additional indication of Imbruvica (ibrutinib) for the treatment of patients with Waldenström's macroglobulinemia, a rare type of B-cell lymphoma. In 2014, the company acquired Alios BioPharma, Inc., a privately held clinical-stage biopharmaceutical company focused on developing therapies for viral diseases.
Bristol-Myers Squibb. Bristol-Myers Squibb reported 2014 revenues of $16. 385 billion, down 3% year over year. The company expects worldwide revenues between $14.4 billion and $15.0 billion in 2015.
On a product basis, a key development for 2014 was the US approval of Opdivo (nivolumab), the company's PD-1 immune checkpoint for treating advanced melanoma. Opdivo is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following Yervoy and, if BRAF V600 mutation positive, a BRAF inhibitor. Opdivo is also being developed for other cancer indications. Bristol-Myers Squibb has a broad, global development program to study Opdivo in multiple tumor types, which consists of more than 35 trials, as monotherapy or in combination with other therapies, in which more than 7,000 patients have been enrolled worldwide. Among these are several potentially registrational trials for non-small-cell lung cancer, melanoma, renal cell carcinoma, head and neck cancer, glioblastoma, and non-Hodgkin lymphoma.
Going ahead in 2015, key issues for the company will be changes in executive leadership. Bristol-Myers Squibb announced several leadership changes approved by its board of directors and effective at the close of its annual shareholders' meeting on May 5, 2015. Chief among them is that Giovanni Caforio, MD, now chief operating officer, will become CEO of the company, and Lamberto Andreotti, now CEO, will become executive chairman of the board of directors on May 5 and will continue to serve as chairman after his retirement on August 3, 2015.
On the manufacturing front, in November 2014, Bristol-Myers Squibb announced plans to construct a large-scale biologics manufacturing facility in Cruiserath, County Dublin, Ireland. The facility will produce multiple therapies for the company's biologics portfolio and will increase Bristol-Myers Squibb's biologics manufacturing capacity. The 30,000-square meter project will house six 15,000-liter bioreactors and a purification area as well as office and laboratory space. The plant will be built on the grounds of the company's existing bulk pharmaceutical manufacturing plant. Bristol-Myers Squibb's board of directors has approved initial funding that will support the first phase of the project. The full cost of the facility, expected to be finalized in the second half of 2015, is anticipated to be comparable to the approximately $900-million investment to construct and operationalize the company's biologics manufacturing facility in Devens, Massachusetts.
AbbVie. In 2014, AbbVie reported net sales of $19.960 billion, up from $18.790 billion in 2013. On a product basis, sales increased 7.1% on an operational basis (excludes the impact of exchange-rate fluctuations) and 5.8% on a reported basis to $19.879 billion. Sales of its key product, Humira (adalimumab), which accounted for 63% of 2014 product sales, increased 18.9% on an operational basis and 17.7% on a reported basis to $12.543 billion. Humira is indicated for treating rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis. A key issue for AbbVie in the near-term is the patent expiry for Humira. The United States composition of matter (i.e., the compound) patent covering adalimumab is expected to expire in December 2016, and the equivalent European Union patent is expected to expire in the majority of European Union countries in April 2018.
As a means to diversify its product portfolio and pipeline, in 2014, AbbVie made a $54.7-billion bid to acquire the specialty pharmaceutical company, Shire, a proposed bid that was later terminated. AbbVie's proposed acquisition of Shire involved a tax inversion structure by which the New AbbVie was to become a holding company for the combined AbbVie and Shire and which was to be incorporated in Jersey, the UK, Shire's current place of incorporation. Through its incorporation in the UK, the AbbVie board expected the transaction to reduce New AbbVie's effective tax rate to approximately 13% by 2016. A subsequent notice by the US Department of Treasury, however, which signaled a limiting of corporate tax inversions, cast uncertainty as to this practice, so AbbVie decided to terminate the proposed acquisition.
Looking ahead, hepatitis C is a key product focus for AbbVie. In January 2015, the European Commission granted marketing authorizations for AbbVie's all-oral, short-course, interferon-free treatment of Viekirax (ombitasvir/paritaprevir/ritonavir tablets) + Exviera (dasabuvir tablets). The treatment was approved with or without ribavirin (RBV) for patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with compensated liver cirrhosis, HIV-1 co-infection, patients on opioid substitution therapy and liver transplant recipients. Additionally, Viekirax was approved for use with RBV in genotype 4 (GT4) chronic hepatitis C patients.
Viekirax consists of the fixed-dose combination of paritaprevir 15 0mg (NS3/4A protease inhibitor) and ritonavir 100 mg with ombitasvir 25mg (NS5A inhibitor), dosed once daily, and Exviera consists of dasabuvir 250 mg (non-nucleoside NS5B polymerase inhibitor) dosed twice daily taken with or without ribavirin, dosed twice daily. With this approval, AbbVie's treatment is now licensed for use in all 28 member countries of the European Union(EU) and was previously approved in the US, Canada, Switzerland, Iceland, Liechtenstein, and Norway. Paritaprevir, one of the active ingredients in Vierkirax, was discovered during the ongoing collaboration between AbbVie and Enanta Pharmaceuticals for hepatitis C protease inhibitors and regimens that include protease inhibitors. Paritaprevir was developed by AbbVie for use in combination with AbbVie's other investigational medicines for the treatment of chronic hepatitis.
In 2014, AbbVie expanded its manufacturing facility in Sligo, Ireland. The expansion provides increased manufacturing capacity for the company's existing product portfolio as well as new therapies within the company's pipeline. AbbVie's presence in Ireland also includes locations in Dublin and Cork, as well as a second plant in Sligo at Ballytivnan. Also in 2014, AbbVie announced it will invest $320 million to establish operations in Singapore for small-molecule and biologics active drug substance manufacturing. The completed facility will provide manufacturing capacity for emerging compounds within AbbVie's oncology and immunology pipeline to serve markets globally. The investment will establish the first manufacturing presence in Asia by AbbVie. AbbVie anticipates the new facility will be fully operational by 2019.
Eli Lilly. For the full-year 2014, Eli Lilly and Company reported a 15% decline in revenue to $19.6 billion. In commenting on the results, John C. Lechleiter, Lilly's chairman, president and CEO said: "Despite the loss of significant revenue for Cymbalta and Evista following the expiration of our US patents, we saw strong performance from many other products. At the same time, we made excellent progress with our innovation-based strategy, and we continue to advance our pipeline. Throughout the balance of this decade, we aim to drive revenue growth and expand margins as we offer new medicines to the people who need them."
In 2014, Eli Lilly received approval for Trulicity (dulaglutide), a drug to treat Type 2 diabetes, and Cyramza (ramucirumab), a drug to treat patients with advanced stomach cancer or gastroesophageal junction adenocarcinoma and which was later approved for treating, in combination with docetaxel, metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy. In addition, Eli Lilly is partnered with Boehringer Ingelheim for Jardiance (empagliflozin), a drug for treating Type 2 diabetes, which also was approved in 2014 and which is part of the companies' diabetes alliance. In January 2015, Lilly also completed its $5.4 billion acquisition of Novartis' Animal Health Division.
As of press time, Merck & Co., AstraZeneca, Sanofi, and GlaxoSmithKline had not reported their results but were scheduled to do so in early February 2015.


text:
Hooligan's Legend - YAMAHA RD / RZ 500
The 60s-70s domination in the GP racing circuit by MV Agusta are well known and also their 17-year win streak. Then came a certain Japanese company with a gill valved 2 stroke 500cc machine ridden by none other then the Italian Mastreo Giacomo Agostini which blew away MV. Some years later, Kenny Roberts won 3 consecutive GP titles with the same machine and then the whole world wanted to know what it feels like to ride the Yamaha YZR500!
And then in the mid 80s, it happened! Yamaha introduced their YZR500 replica (and it was almost same to the original), the 500cc V-Four RD. Till Ducati NOW launched the RR, this bike was probably the closest to a real GP bike one can get to drive. Think about it... Its a 2 stroker firstly, water cooled (2 strokers are known for heating up, so the water cooled would only add to the fun), and its a V-Four! How awesome! I ride a RD350 and their are no limits to the fun that RD delivers, but then the RD pales badly in comparision to this mean machine. The styling is also GP style with full fairing in a box section frame.
Like like its elder sibling, it also had its variations. While the 350 has varied engine specifications like 30 bhp, 39 bhp and a LC model, the 500 variations were same from the engine, but sported different tyres and paint jobs and was also known as RZ500 in some markets. In Europe the RD500 had Michelin Tyres, while in Australia, New Zealand and Canada, the RZ500 had Yokohoma tyres besides a different paint job from its European counterpart. Interestingly it never made it to the US for emission norms. Japan had its own model, a limited-edition RZV500R, with a aluminum frame instaed of the regular steel model and it had a de-tuned engine.
The RD/ RZ used a 50-degree, twin crank V-four motor equipped with Yamaha's YPVS (Yamaha Power Valve System) exhaust power valves with removable cassette-style six-speed gearboxes. The differences from the actual GP bike was that had rotary valves to control intake compared to the street version which used reed valves. This was given to achieve a broader, more street-oriented powerband. The lower cylinders were fed through crankcase reeds; the upper pair used cylinder reeds, with 90 degree intake manifolds connecting each reed block to it's side-mounted carburetor.
There was also a counter balancer, which is quite unusual on a two-stroke, helped dampen engine vibration. The YPVS system bolstered low and mid-range power, and let gasses flow into four individual expansion chambers. The lower exhaust pipes are as par any 2 stroker, while the upper pipes cross over each other just above of the exhaust ports to help maintain proper tuned length. This king of a menacing machine had to have a 5 figure redlined rpm!
But there was one thing where the 350 was better than the 500 and for that reason the 350 was a bigger legend and more well known model. The initial surge!!! That was where the 350 scored heavily. In the 500, there was a distinct lack of power below 6000 rpm coupled with a tall first gear make the RZ rather difficult to get away from a stop. But once it catches up the 350, say at the 7000 rpm line, then it will just burst out!
The 350 came alive once you reached 3000 rpm where as the 500 comes alive above 6500 rpm. After that this 500cc 2 stroker producing a mighty 80 bhp was in the control of Gods cause no mere mortal could have ever controlled this beast! 80 bhp is like 120 bhp on a 4 stroker and so muc coming out from a 500cc engine and re,ember this was a street version. And thats not all, you can further tweek the engine for additional 4-5 bhp!
And the Torque! The RD series was all about Torque. Any hills, how steep it is hardly mattered for the RD. Still today, it can easily outrun any 600cc sportsbike. the power torque peaked at an amzing 48.3 ft-lb at 8500 rpm, with the curve remained flat all the way up to the 10,000 RPM redline, so it could pull up from anywhere, doesn't matter if you were idling at 40kmph at 300rpm, it will just ...rush!
The second photo is a 2008 - RD 350R V4! Actually, a fan creation of the legend what it would look like in the present scenario. Size is 1600 x 1200 with high resolution. Can be used as a wallpaper.
The bike also had a very high center of gravity as the under-seat area had the YPVS motor, the battery and the upper cylinder pipes. This helped the chassis a lot and the bike was extremely flickable due to it. Overall, the RD/ RZ was a small bike but did weigh quite a lot at 200kgs, but with a low center of gravity, short wheelbase (53 - 54 inches), and a racer-like 26-degree steering head angle, it was the wolf in sheep's clothing. You could even corner it as 180kmph (depending on your skills) or even ride the whole day withour streching your arms and back because it had a very comfortable feel, as bikers say... sitting "IN" it and not "ON" it. The twin disc brakes up front and the single at the rear disc which were ventilated offers enough confidence. Really, with modern technolgy, engineers have given us too many choices to spoil us, from a LC Fi engine on a 150 cc 4S engine to ABS on a tourer, there are so many choices, but... then you can have all the available bikes today in a platter and give me a 2 stroker instead... any day!
Specifications- (RD350LC)
Engine: 499cc, 2S, LC, reed-valved 50-degree V4
Max Power & Torque: 88 hp 65 kW @ 9500 rpm & 67 Nm 6.8 kg-m @ 8500 rpm
Bore x stroke: 56.4 x 50.0 mm
Carburetion: 4 x 26mm Mikuni
Transmission /Drive/Compression Ratio: 6 Speed/Chain/ 6.6:1
Front & Rear Suspension: 37mm Air assisted telescopic forks, 4-way spring preload adjustable and anti-dive variable. 140mm wheel travel / Monoshock, spring preload and rebound damping, 120mm wheel travel.
Front & Rear Brakes: 2x 267mm discs 2 piston calipers / Single 245mm disc 2 piston calliper
Front & Rear Tyre: 120/80 V16 //130/80 V18
Wheelbase: 54.1 in. Seat height: 31.5 in.
Dry-Weight / Wet-Weight: 173 kg / 198.6 kg
Fuel Capacity: 22 Litres
Consumption Average: 12 kmpl (~27.5 mpg)
Standing ¼ Mile: 11.7 sec / 117.7 mp/h
Top Speed: 237 kmph (~148 mph)


Your Solution – Brendale: 1/6 Pine Rivers office Park, Cnr Leitchs & Southpine rd.
Wickham House Pharmacy. 157 Wickham Terrace, Brisbane.
Please email us at goldcoast@acpharm.com.au or call 1300696337 for further information.
ACPHARM Gold Coast have a 24 hour to 48 hour turnaround with all order.
Bio-identical Hormone Troches from $25 to $40 and postage is $9.95.
Being Australia's Largest Compounding Pharmacy group we can offer these amazing prices with the same great quality and customer service.
You could try us (Prime) if you are looking for somewhere new to try Vanessa. I won't pass comment on any other compounding pharmacies service as its not how I do business. But to do with me, While its probably just luck, at least a couple of patients have left me happy enough to post here about my compounding Pharmacy.
We are a little out of the way in Dayboro but its one of the more professionally setup labs in QLD and I can have your compound delivered to you. I can also usually have it sent later on the same day as well.
3.ACPharm Gold Coast $35 (+$10 O'night 'Fastway Couriers' to Sunshine Coast) and these dissolve better than 2. Del did take 2days, driver apologised, normally only 1day. Time will tell.
I encourage patients to compare compounding chemists, as it keep them on their toes and competitive.
I have used Morayfield Compounding Chemist, Your Solution & most recently Prime Compounding @ Dayboro. My pick is most definitely Prime Compounding! Andrew delivered great customer service, their prices were better, their postage is reasonable & the turnaround time unbeaten.
Sorry, pushed send by accident…..
Also, thank you for taking the time to say something, being in Dayboro we rely almost exclusively on word of mouth for our business. So your words really do mean a lot to us.
Thanks for that feedback. I am interested in any comments about service from the various comppounding chemists, as that will help me decide whom to recommend. Also, any comments about service from my receptionists is also welcome.
Important feedback. Helps others as well.
If you are still having trouble, my name is Andrew and I'm the owner of Prime Compounding in Dayboro. We provide same day service (pickup) or next day delivery if a script is received before 1pm. I have to put a disclaimer in, just in case there is a really uncommon ingredient that we don't stock, in which case it may take a day to get it sent to us.
Our prices for troches are either $60 or $70 flat (depending on the strength and number of ingredients). We have two purpose built labs and we use PCCA ingredients (as Dr Holloway recommends), just so you can be sure we aren't cutting any corners.
Dr Holloway, I have a friend in Melbourne who would also love to benefit from your treatment. Is there somewhere in Melbourne she can go for similar treatment, that you can recommend?
And we also match competitors prices with free shipping and the best customer service. http://Www.ozcompounding.com.au . Thanks Dr Holloway!
I can have them posted today if this helps? I would just need a fax/email copy of the script.
Thanks for letting us know. They are new on the list since I last looked. I use Terry White Windsor but have not been overly happy with them. They quote one price on phone, then charge more to credit card. At least give credit or refund when queried. I request Couriers Please, they send Aust Post. I request it to be sent to address at Coast where I spend a lot of time, they send it to my other inland address. etc.etc.etc. But their prices are good when compared with others, as I have done a few times over the last 7 years. And Mary-Lou is very helpful/informative if you have questions.
Compounding Pharmacy Morayfield. Shop 12, Morayfield Village. Next to Morayfield Doctors Med. Centre .
Carolyn, it would be handy if you could tell us which compounding chemist is giving you such poor service???? Hope things are resolving for you by now.
This is unacceptable. This sort of feedback is important to me, as it helps me decide which compounding chemists to recommend, which provide the best service, and best value for money. So feedback from all of you as to your experiences of the various compounding chemist is important to me.
I have been off Premarin for two weeks now and the symptoms are diabolical. I saw Dr Holloway one day after stopping Premarin, had a blood test and got my prescription a week later. That was last Monday. I submitted my prescription on the same day. They said they needed to check with the doctor before making it up and would do so immediately. It is now Wednesday afternoon so I called the chemist wondering where my troche is. She rudely responded that they are busy with other patients and that she only spoke to the Doctor Tuesday afternoon. She hadn't started the troche and she would call me on Friday. I haven't slept for a week, am moody and irritated, and having hot flushes and migraines all the time. Every day seems long and tortuous without relief. Should I go back on Premarin before I kill my family?
The chemist needs to understand, our sanity is in her hands, so treat us nicely please. Does Dr Holloway know the scripts take this long? If it's not ready on Friday it will be three weeks since I have had any hormone therapy. I need some relief soon.
I used to get my troche from Jack Hammond at Broadbeach Amcal Pharmacy and the price was great, but now he has gone and the price has gone up and it tastes different. Do you know where I can find him now as he was always good with advice and price. I hope he is still compounding. Thanks.
Shop around. Most compounding chemists charge much less than that.
I've just started on natural hormones….estrogen only….through the Australian Menopause Centre and it costs me $81 per month!
Hi Jenny, thank you for your comment. I have reviewed your concerns and noted the price increase was from the increase of dose one ingredient at 100% and another ingredient 33%. With regards to your pregnenolone capsules, our price for pregnenolone has slowly doubled since you first come to us and last year was the first time we have made a price adjustment to reflect our increase cost so it might have seemed to be a big jump.
Sorry! It was for my trouche – Prog, Ttiest.
What was it that cost $70????????????
Mine recently cost $70 from Yandina, though I see the Yandina Pharmacy is not on Colin's recommended list.
I have been using Maroochy D&N for my compounding scripts for several years now. Recently (in last 12m) my script prices have increased from $65 to $88 for Prog,Test,Biest Cream and from $94 to $127 for Pregnenolone Capsules. Have other people experienced similar increases or is it time for me to find a new supplier???


text:
RLetters Help
Analysis Workflow
Analysis Tasks
Dataset Management
Why am I seeing help for something called "RLetters"? I was using (some other site)
RLetters is a software package that allows anyone to build an archive of journal articles that can be searched and analyzed. While users of RLetters could create their own help websites, it's often easier for them to link back here – to the main RLetters help site, which we keep updated and current. While some things may look a little different at the website you were using, most of what you see here should translate without any trouble. If not, let the RLetters team know, or contact the folks who run the site you were using.
I selected my language in the user preferences, but all the text is still in English
The list of languages indicates all the languages in which it is possible to translate the application. For most of these languages, the bulk of the translation work has not yet been done. If you'd like to contribute translations in your native language, we'd love to have them: please visit the contributing translations page at the development website for more information about how you can help.
Do RLetters-powered websites use cookies?
Yes, but only to store a very small amount of data about whether you're logged in and to enable the "Remember me" function for logins. You can visit a page containing information about cookie usage in two ways:
Click "Help", then "User data" in the navigation bar. There should be a link to the cookie policy on that page.
Clear your browser's cookies, reload the site, and select "More information" in the cookie warning which appears.
The CiteULike link returns a "page not found" error or shows me the wrong document
These connections with other systems are only as good as the results that they make available to us, and (due to technical limitations), we can only perform title-based searches to connect documents here to external documents. A "page not found" error means that title-based search received no hits, while returning an incorrect document simply means that the top search hit for the title of the document you're looking for isn't the right document. You can try to search for these documents directly on the respective external websites.
All content copyright © 2010–2018 Charles Pence. All web content is released under CC-BY-NC-SA 3.0.
Code is released under the MIT License. RLetters logo taken from a photograph by Leo Reynolds.


You are here: Home / inspiration / 7 Weapons At A Christian's Disposal.
7 Weapons At A Christian's Disposal.
Weapons are instruments that can be used to achieve something. It is always very important to go to a battleground with the right weapons. David faced Goliath with the right weapon. If David had gone to that battle with the wrong weapon he would have been killed by Goliath.
The lesson that can be learned from this is that as Christians, it is very important to know which weapon is best suited to fight a particular opponent. Once this is known, the battle is half-won. Now, this article will provide Christians with seven spiritual weapons that they can use in spiritual warfare. It is hoped that by the end of this article, the Holy Spirit would have opened the eyes of one or more readers and a change would be effected in that life.
The following are 7 weapons at a Christian's disposal for a victorious spiritual life.
Prayer is a very important weapon in the life of all believers. Prayerfulness is one of the key weapons in Christianity as emphasized by our Lord Jesus Christ. He recognized the importance attached to praying, which was why at every stage in His life he always prayed.
In the King James Version of the Bible, the word pray was mentioned over 300 times. This goes to stress the importance that is attached to praying. It is indeed a fact that a prayerful Christian is a powerful Christian and there is absolutely no one that can dispute that.
In the book of Luke 11:1, the Bible says "And it came to pass, that, as he was praying in a certain place, when he ceased, one of his disciples said unto him, Lord teach us to pray, as John also taught his disciples". From this passage, two things are noticeable. The first is that Jesus never really had a particular time or place that he prayed. The second is that he prayed ceaselessly.
No wonder in the book of 1 Thess. 2:13, the Bible says we as Christians should "pray without ceasing". A prayerless Christian is one who can be tossed about by the winds of the "Principalities and Powers" that we war against. Another thing that can be learned from this passage is the fact that the disciples were eager to learn to pray. In the world today, there are many Christians who are called Christians just because they go to church. That is never the real meaning of that word. As Christians, we are supposed to be Christ-like. If Christ never took prayers lightly, Christians should never take prayers lightly also.
In the world today, there are many Christians who are called Christians just because they go to church. That is not the real meaning of that word. As Christians, we are supposed to be Christ-like. If Christ never took prayers lightly, Christians should never take prayers lightly either.
This is a very key weapon in the hand of a believer. Praise is very important as many powerful men of God in the Bible made use of it. One very prominent example, of course, is David. David used most of his books to praise God. Especially in the book of Psalms, he never ceased to give God all the glory and praise. In fact, the praise that David regularly gave to God regularly spurred God to forgive him even after committing a sin as grievous as murder.
If a Christian recognizes the power that is attached to praise and fully harnesses that power he or she is definitely bound to accomplish spiritual victories. It was the powerful weapon of praise that saved Paul and Silas in the bible when they were in prison. In the book of Acts 16:19 the bible says "And at midnight Paul and Silas prayed, and sang praises unto God: and the prisoners heard them." Paul and Silas were in prison and they were in grave danger. Did they shiver? No! They sang praises unto God because they knew that there is an importance attached to praise. So as believers, we should learn to realize the power that is attached to praise and as we do things will begin to change for good.
This is in fact, one of the most important weapons at a Christian's disposal. It is the most important because faith is the activator of all other weapons. In the book of Hebrews 11:1 the bible says "Now faith is the substance of things hoped for, the evidence of things not seen." Therefore, it is important to note that faith is very key in the life of a Christian. Simply put, faithlessness leads to fruitlessness in the spiritual realm and in the same manner, faithfulness leads to fruitfulness.
This is a very important weapon in the life of any believer. In spiritual warfare, a Christian can never do without the word. The word is very important and a good knowledge of it is required by any Christian. In the book of 2 Timothy 2:15, the Bible says "Study to shew thyself approved unto God, a workman that needeth not to be ashamed, rightly dividing the word of truth". It is because of the power that is attached to the Word that Paul instructed Timothy to always study the word.
A very good example can be seen in the book of Matthew 4 when Jesus was led up into the wilderness and the devil came to tempt him. In that passage, there was a spiritual warfare and the only weapon that was used was the Word. Let us be careful as well to know the word deeply and whenever we are confused, let us ask the Lord for guidance and insight.
Even Jesus recognized the importance of this weapon. While he was led by the spirit into the wilderness in the book of Matthew 4, he fasted. In verse two of that chapter, the bible says "And when he had fasted forty days and forty nights, he was afterward an hungered". Fasting is very important in the life of believers, in fact, Jesus made us know that there are some problems that cannot be solved unless the Christian prays and fasts.
That's how important it is. Also, to show you how important fasting is as a weapon in Christianity, Jesus fasted for forty days and forty nights! Now, the big question is, how many Christians today can emulate our Lord Jesus and recognize that fasting is a weapon in spiritual warfare? The earlier we realize the importance, power, and efficacy of this weapon, the better for us. We will be able to move spiritual mountains because of the strength gained from the self-sacrificing act of fasting.
Now, I know that this might sound a little off but the truth is that it is not. When you give your tithes and offerings to the Lord and give to the needy, you will automatically unlock the gates of abundance. A Christian that does not know how to give will always lack. The lack will not only be in the physical realm, it will also be in the spiritual realm. He or she will lack the weapon needed to fight well and win in the spiritual realm.
This is confirmed in the book of Malachi 3:10 "Bring ye all the tithes into the storehouse, that there may be meat in mine house, and prove me now herewith, saith the LORD of hosts, if I will not open to you the windows of heaven, and pour you out a blessing, that there shall not be room enough to receive it". It is a very important aspect of the Christian race. Give and it shall be given unto you and of course, when you give, you will activate the efficacy of that weapon.
This is also a very important weapon to a Christian. In many cases in the bible, the inappropriate use of the tongue has led to the downfall of many. In fact, in the case of Ananias and Sapphira, it was the inappropriate use of their tongues that led to their death. The tongue can be used negatively in many ways, it can be used to lie, it can be used to covet, it can be used to backbite, and it can be used to gossip and so on. But as Christians, it should be used properly and of course to the glory of our Lord Jesus Christ. It is advised that as a Christian, you should always decree positivity.
This is really important because the power of the tongue has been explained many times in the bible. It is advised that as a Christian, you should always decree positivity. In the book of Proverbs 18:21 the bible says "Death and life are in the power of the tongue: and they that love it shall eat the fruit thereof". Whenever you are down, whenever you feel depressed, do not speak negative things. Always praise God and declare positive things into your life.
If you continue to declare negativity, in time whatever you declare will materialize. So, as Christians please do not at any point in time say negative words or assertions to someone or even to yourself. Remember, the tongue has the power to kill and also to keep alive. It is a weapon, use it well.
There you have it, seven weapons at a Christian's disposal. Use these weapons well to experience spiritual victories and harness God's best for your life.
I do hope that this article has been a blessing to you all. Stay blessed and continue to live in his glory!!!
thepraywarrior.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon. Certain content that appears on thepraywarrior.com comes from Amazon Services LLC. This content is provided 'as is' and is subject to change or removal at any time.


text:
Home → Articles → Utah → Drop by Drop
Drop by Drop
Wendy Bowden Crowther helps her clients preserve and secure rights to Utah's water sources
Published in 2010 Mountain States Rising Stars magazine By Adrienne Schofhauser on June 17, 2010
When Wendy Bowden Crowther visited Mesa Verde National Park in southwestern Colorado a few years ago, she stood in awe of the preserved ruins left by the ancestral Pueblo people. Gazing at the stone structures, she realized something particularly astonishing.
"I'm standing in the middle of this hole and I'm like, 'Oh, my God, it's a reservoir,'" Crowther says. "It's fascinating that they were manipulating water and managing it almost 2,000 years ago."
Crowther had reason to be intrigued. At Clyde Snow in Salt Lake City, the 45-year-old shareholder represents contemporary water wielders—from the individual farmer to large water districts—in their resource management. Since joining the firm right out of law school at the University of Utah in 2000, she's focused on natural resources law with an emphasis on water law and litigation.
A huge part of Crowther's practice is helping clients buy, sell and protect their rights to the finite resource. "A lot of what we're dealing with is trying to figure out how modern needs for conservation are going to come together with this hundred-year-old [Utah] law that is based primarily on use," she says. "Whoever uses it first gets to keep using it, no matter how they use it and no matter how much they use."
Crowther hopes the law will change with conservation trends. Through her roles in the state bar and as chair of the American Bar Association's Water Resources Committee, she stresses the importance of conservation tactics such as rain- and storm-water harvesting.
Crowther was drawn to water law because of a love of the outdoors and her degrees in history and anthropology. "Water has a lot of history, particularly in the West," she says. Many of Utah's water rights date back to the founding pioneers' entry into the Salt Lake Valley, and Crowther often finds herself researching historical title documents that stretch back beyond the founding of the state. "Even when you're working with the individual farmers or ranchers that own water rights, they've got these family histories that are tied to this land," she says.
The history of the West continues to dictate today's water policy. In Strawberry Water Users Association v. the United States, Crowther and her firm represented one of several defendants in a dispute grounded in water rights for land that dated back to 1900. She helped argue against the Association's claimed rights to use of facilities on a project that moves water from the Colorado River to a swath of urban area. "It was a very complicated case with federal water issues, state water issues and contract issues," Crowther says. The case stayed in federal courts for nine years until last August, when the 10th U.S. Circuit Court of Appeals affirmed a prior U.S. District Court ruling that the rights belonged to the U.S. Bureau of Reclamation—a victory for her client.
Not all of her cases are so complex. Sometimes, she's just out scouting the landscape, investigating water works projects for clients. "I love those two sides of water," she says. "One day you're standing there in a suit in a courtroom, and the next day you're in your jeans and your hiking boots out on the canal."
Either way, it's history in the making.
Wendy Bowden Crowther
Top Rated Energy & Natural Resources Lawyer
Parsons Behle & Latimer
Catching the American Dream
Five Georgia attorneys tell their immigration stories Featuring Georgetta Glaves-Innis, Soo J. Hong, Neeli Shah, Dina R. Khismatulina, Shirley C. Zambrano
Six pillars of the legal community look back on three decades of law Featuring Nancy Zalusky Berg, Michael V. Ciresi, Joseph S. Friedberg, Earl P. Gray, Kathleen M. Newman, Lewis A. Remele, Jr.


text:
As ever, our best albums of 2019 so far list reflects the diverse tastes of the Exclaim! writers list, but this was a little different. Where lists of yesteryear tended to be topped by albums that absolutely sprinted away with the votes (Cardi B and U.S. Girls were miles ahead of the rest of the 2018 list; Kendrick Lamar, Sampha and Feist dominated the voting in 2017), this year's votes were more evenly dispersed — it wasn't until the last few votes came in that even the top five became clear.
Maybe that's further evidence of the monoculture's breakup, or maybe the 2019 album that unites everyone across genres hasn't come out yet. In the meantime, there's plenty of debate to be had about these 29 long-playing feats of style and musicianship. Dig into Exclaim!'s Top 29 Albums of 2019 So Far below, and get arguing.
29. Deerhunter
Why Hasn't Everything Already Disappeared?
(4AD)
From their amorphous dream-psych beginnings to the more whimsical, sharply contemplative vision of their eighth album, Why Hasn't Everything Already Disappeared?, Deerhunter have existed in a hazy divide between alluring guitar rock and spacious, hypnotic experimentations. Here, the Atlanta band continue to follow their sonic impulses by blending some of their strongest pop hooks yet with the full spectrum of their bizarre, colourful pastiche.
The waltzing, harpsichord-led "Death in Midsummer" darts between exquisite and obscene, while the shimmering "What Happens to People?" is densely packed with bandleader Bradford Cox's pastoral musings and a deceptively cheery piano riff, lurching between glistening guitars and an ornate drum beat. The contrast between the fragrant reverie of the airy vocal exchange between guitarist Lockett Pundt and co-producer Cate Le Bon on "Tarnung," and the bubbly funk on "Plains" that follows, prove that Deerhunter aren't afraid of magnifying the peculiarities of their ever-expanding sound.
28. Aldous Harding
Designer was everything listeners anticipated from Aldous Harding's third full-length, and a lot that wasn't — and that's what makes it so special. Harding has a way of making the uncanny tangible, and Designer delivers once more, providing the feeling of stumbling onto a lone stranger dancing naked in the middle of the woods, and knowing exactly how to join in without missing a beat. For those awaiting this latest release with bated breath, it was this familiarity, presented via oddity, that came to satisfy us once again, filling something we didn't know was empty with a multitude of rich, unusual classics.
Ariel Matheson
27. 2 Chainz
(Def Jam)
Five albums into a hard-earned but now glittering career, it was beginning to feel ambitious to ask for anything beyond pretty girls and trap music from 2 Chainz, which is why Rap or Go to the League — a reference to both a personal career crossroads and the limited escape routes of so many young black men from fractured homes — is so refreshing in its honesty and its excellent, soul-infused beats.
"I did some things I ain't proud of, like sold my mom drugs / The devil put somethin' toxic in me / Demons tryin' to have an auction in me," Chainz confesses on highlight "Threat 2 Society." So what if LeBron James couldn't lead his team to the NBA Finals this year? He was busy executive-producing one of the year's best no-nonsense hip-hop LPs.
26. Jayda G
Significant Changes
(Ninja Tune)
There aren't many out there who can mix old-school disco cuts with environmentalism, but Vancouverite Jayda G appears to be one of them. After completing her master's degree in Resource and Environmental Management, she named her debut album Significant Changes, after the most commonly used phrase in her thesis.
She could have left the nod to academia at that, but the record is rife with references to her studies. "Missy Knows What's Up" quotes dialogue from biologist Misty MacDuffee, while "Orca's Reprise" samples whale calls atop a tender arrangement of strings. All the while, fresh approaches to disco are bookended by offbeat club tracks and downtempo excursions. It's a surprising album from a producer whose consistency now comes as no surprise whatsoever.
Daryl Keating
25. Nilüfer Yanya
(ATO Records)
Fuelled by extraordinary hype and a handful of expertly crafted EPs, Nilüfer Yanya's steady trajectory seemingly needed just one more thing: a definitive full-length album.
Yanya's debut, Miss Universe, is equal parts brilliant and spontaneous, veering from soul-tinged R&B to Doolittle-era Pixies-isms like it's inherent. Lyrically, Yanya constructs a similar balancing act, obscuring the lines between desperation and violence: "Yeah, all I really want is / Somebody to stop me / Somebody to hold me back / It gets worse if it's not you / I'll be lyin' in a pool of someone else's blood," she sings on "Tears."
Tempered by Yanya's remarkable voice, the laser-sharp clarity that permeates Miss Universe is as incisive as it is inviting. Though she was already operating at a level far beyond her peers, Miss Universe provides a dose of validation.
Calvin Cashen
24. Whitechapel
There's been a bit of a deathcore revival lately, but rather than doubling down on blast beats and breakdowns for that retro appeal, Knoxville, Tennessee's Whitechapel transcended it on this year's The Valley.
There are still those key building blocks, but it's the mortar that holds them together that really shapes the album. Vocalist Phil Bozeman croons like Corey Taylor or Maynard James Keenan, while his bandmates complement his always-impressive vocals with mood-appropriate musical musings. A tender tune like "Hickory Creek" makes the raw rage of "Forgiveness Is Weakness" terrifying. The palpable emotions, which confront childhood trauma and abuse, only make it more so.
"When a Demon Defiles a Witch" splits the difference between fury and feeling, resulting in the best chorus — in the traditional sense — deathcore has ever produced.
Funnily enough, despite renewed interest in the once-maligned subgenre, the best thing to come from deathcore in 2019 is the one album that risked stepping away from it.
Bradley Zorgdrager
23. The Chemical Brothers
No Geography
(Astralwerks)
Part of the promised wave of European acts that were going to take over North America in the mid-'90s, the Chemical Brothers have always embodied the blissed-out harmony of the UK's summer of love and the acid-drenched breakbeats that fuelled the early DIY rave culture in the UK. This is not a Hollywood style do-over where the band just recreate nostalgic moments and end up as a hollow version of themselves.
That doesn't mean Ed Simons and long-time partner Tom Rowlands don't use some of the foundations of early Chicago house, dialled up Detroit techno, wide-eyed acid and neon-splashed breakbeats on their ninth studio album, and first release in four years. In a genre that can change faster than the digital store algorithms can keep up, the Chemical Brothers' use No Geography to remind people how their strobe-blasting, body-rocking, sensory-overloaded live shows in the new millennium paved the way for what you see at every big stage electronic festival in 2019.
Anthony Augustine
22. Bring Me the Horizon
(Sony)
BMTH continued their unstoppable rise with amo, the most mainstream and experimental album they've produced yet. Gone are the days of the deathcore scene kids; in their place, we have some of the best pop metal tracks ever put to record, including "Mantra," "Medicine," "Mother Tongue" and "Sugar Honey Ice & Tea." Embracing a sugary, electronic-infused sound 15 years into your career would be cyanide for most metalcore acts, but BMTH have never really cared what people think of them. Or, as the meta-lyrics to the song "Heavy Metal" state: "This shit ain't heavy metal, and that's alright."
Max Morin
21. Charly Bliss
(Barsuk)
Like any great power pop group, Charly Bliss have mastered the art of propulsive, infectious melodies. And like any great pop record, Young Enough is energetic and fun, with no excess fat, perfectly optimized to deliver all the highs of contemporary indie pop.
But this record has more tricks up its sleeve. The title track and "Hurt Me" feature evocative vocal performances from Eva Hendricks, and heart-wrenching lyricism, but most notable is the bright and danceable "Chatroom." Written after Hendricks was sexually assaulted by someone she dated, she's talked about how the song is a celebration of shaking off past trauma and feeling strong again.
It's moments like these that speak to the sheer growth the band have undergone, and how they can turn moments of pop exuberance into ones that carry significant heft — ones you'll want to return to again and again.
Matt Yuyitung
METAL AND HARDCORE
More Sharon Van Etten
More Tyler, the Creator
More James Blake
More Deerhunter
Sharon Van Etten Takes on Two Christmas Classics
Sharon Van Etten has shared her own spin on two versions of Christmas classics, "Silent Night" and "Blue Christmas." Both tracks arrive t...
Local Natives Detail New EP 'Sour Lemon'
Following last year's Violet Street, Local Natives have returned with details of a new EP. The band will release the four-track Sour Lemon o...
Sharon Van Etten Covers Nine Inch Nails' "Hurt"
Sharon Van Etten has teamed with Sound of Saving and the National Suicide Prevention Lifeline to release a benefit single as part of Nationa...
R.E.M, My Morning Jacket, Phoebe Bridgers, Angel Olsen Join Massive Benefit Compilation
Dozens of musicians have come together on a massive compilation benefitting American democracy ahead of the U.S. election later this year. T...
Fountains of Wayne Join Forces with Sharon Van Etten for Reunion Show in Honour of Adam Schlesinger
Fountains of Wayne have announced their first live performance in seven years to pay tribute to their fallen bandmate Adam Schlesinger, who...
Freddie Gibbs Proves He's One of the Best Around on Alchemist Collaboration 'Alfredo'
Freddie Gibbs proves yet again why he is the one of the best rappers right now. Hot off his reunion with Madlib – last year's Bandana – he h...
Stream Freddie Gibbs and the Alchemist's 'Alfredo' Album
Freddie Gibbs and the Alchemist have served up surprise album Alfredo, and you can stream the entire thing right now. The pair announced...
Freddie Gibbs and the Alchemist Team for 'Alfredo'
After teaming with Madlib for the acclaimed Bandana last year, Freddie Gibbs has joined forces with another super producer in the Alchemist...
Tyler, the Creator Calls the Grammys' Urban Contemporary Category "a Politically Correct Way to Say the N-Word"
Yesterday's Grammy Awards saw Tyler, the Creator collect his first-ever golden gramophone, with last year's IGOR capturing the award for Bes...
Here's the Full List of the 2020 Grammy Winners
The 62nd annual Grammy Awards were given out at the Staples Center in Los Angeles last night (January 26). Given the location, Kobe Brya...
Slowthai Details New Album 'TYRON' with Skepta, A$AP Rocky
Slowthai has detailed a follow-up to last year's Nothing Great About Britain. The UK artist will release new album TYRON on February 5 throu...
James Blake Delivers 'Before' EP
Having shared a pair of singles earlier this year, James Blake has now returned with a new EP. You can take in the four-track Before below,...
Slowthai Gets James Blake and Mount Kimbie for New Song
Slowthai once proclaimed that there was "nothing great about Britain," but he's now teamed with two of the U.K.'s best for a new single. You...
James Blake Covers Frank Ocean's "Godspeed"
James Blake had a hand in producing, arranging and playing on Frank Ocean's "Godspeed," and the artist has now shared his cover version of t...
Flatbush Zombies and James Blake Team Up for "Afterlife"
Flatbush Zombies are back with a new single, and they've roped in none other than James Blake to lend a hand. Together, they've released the...
Deerhunter Share New 13-Minute Single "Timebends"
Deerhunter are back with a little Halloween treat — a new 13-minute song called "Timebends." This marks the first new material we've got...
Deerhunter's Bradford Cox and Cate Le Bon Team Up for Joint EP
Deerhunter leader Bradford Cox and Cate Le Bon are joining forces for a new release. Coming as part of Mexican Summer's Myths EP series, the...
Deerhunter's Bradford Cox Designed the Fonts Used on Avril Lavigne and Papa Roach's Classic Albums
Alongside his guitar and vocal duties as frontman of Deerhunter, Bradford Cox has also handled the group's graphic design and typography for...
Deerhunter Danforth Music Hall, Toronto ON, February 21
Compared to their contemporaries of late '00s and early '10s indie rock, Deerhunter are an enigma, incomparable to the likes of Vampire Week...
Deerhunter Reveal the Influence of Cate Le Bon and Whitney Houston on 'Why Hasn't Everything Already Disappeared?'
"How bored are you right now? How bored will your readers be?" Bradford Cox can talk for hours about many topics. Twice in the span of 9...


text:
Higgins Sees Off Selby To Reach Final
Saturday 31 Oct 2015 01:45PM
John Higgins is just one win away from his third ranking title of the year – and 28th of his career – thanks to a 9-4 win over Mark Selby in the semi-finals of the International Championship in China.
Wishaw's Higgins outplayed world number one Selby to set up a best-of-19 frames final against David Gilbert tomorrow in Daqing. Victory would give Higgins the top prize of £125,000, which would be his biggest cheque since winning his fourth world title in 2011.
It would also put him ahead of Ronnie O'Sullivan on the list of career ranking crowns, and level with his boyhood idol Steve Davis, though still eight behind Stephen Hendry's record of 36.
Higgins, who turned 40 in May, went nearly three years without a ranking title after winning the 2012 Shanghai Masters and his best days looked behind him. But he broke that drought by capturing the Welsh Open in February, and he went on to triumph at the Australian Goldfields Open in July. His performances this week – notably a 6-0 thumping of Shaun Murphy and today's comfortable defeat of Selby – have shown that his renowned all-round game is very much intact.
Breaks of 56 and 101 helped the Scot build a 3-0 lead, and though Selby pulled one back, Higgins made an 87 in the fifth then a trademark 58 clearance in the sixth to surge 5-1 ahead.
Leicester's Selby, who is yet to win a title this season, took the last two frames of the afternoon session to raise hopes of a fight-back. But Higgins started the evening session strongly as breaks of 64 and 54 helped make it 7-3, then he cleared from the last red in the next to go five up with six to play. Selby at least forced an interval with a run of 79, but world number 12 Higgins got the better of frame 13 to set up a final clash with 40th-ranked Gilbert.
"I have been very pleased with the way I have played in this tournament," said Higgins. "I feel as if I'm near the top of my game. I concentrated on every frame today and didn't give Mark many chances. We have similar games and it was just my day today.
"David Gilbert has played well this week to get through and it's going to be a great final. All the players know how good he is and he should have done a lot better in his career – he's starting to show that now. I'll just try my best and hopefully give him a good game.
"The crowds here have been great all week and the conditions are perfect, the best I have seen in ten years."
Selby said: "John just played really well from start to finish, he is as good as ever. In the first frame I missed a red to a middle pocket, then I didn't get another chance until I was 3-0 down. I was happy to get out at 5-3, but tonight John was just too strong. He punished me whenever he got a chance. If he plays like that tomorrow he'll be very hard to beat."
Sublime Trump Claims International Title
Trump Takes Control Of International Final
Murphy Holds Off Allen To Make Final
World Snooker
@WorldSnooker1
5 Wenselijk Feiten Over Ondertitelen https://t.co/FKBXvj7thu


text:
YouTubeLinkedinInstagramFacebook
Cameron Engineering & Associates
Top New York and Long Island Engineering Firm
Rich Zapolski, Jr., P.E.
Associate, Civil Engineering
Mr. Zapolski is a professional Civil/Site Engineer with 27 years of experience in Urban Planning and Land Development. He has planning and civil engineering design experience in several sectors including educational, residential, commercial, and industrial land development throughout the northeast, primarily in Suffolk and Nassau Counties, Long Island, NY as well as FEMA NIMS training in Town and County Emergency Operations.
In his former position as Planning Commissioner at the Town of Islip, he was responsible for five divisions of the Department, including Building, Engineering, Planning, Economic Development and Zoning Board of Appeals. Mr. Zapolski served as Committee Member of three GOSR New York Rising – Community Reconstruction Programs, and was instrumental in damage assessment and recovery efforts during and following Superstorm Sandy. Prior to this position, he served as Chief Engineer and was responsible for many civil engineering, drainage, stormwater management and Storm Water Pollution Prevention Plans.
Email: rzapolski@cameronengineering.com
Copyright © 2020 Cameron Engineering


text:
OPRF places 6th in Pontiac Tournament
Recapping three days of boys hoops
Thursday, January 2nd, 2020 12:00 AM
The Huskies played against some of toughest competition in the state (including No. 1 ranked Bloom) from Dec. 26-28. They placed 6th in the tournament (File photo).
Sports Editor
OPRF boys basketball participated in one of the most talent-laden tournaments in the state when it headed to Pontiac for the annual Pontiac Holiday Tournament. The Huskies dueled with Plainfield North, Bloom, Warren Township and Simeon high schools and finished in sixth place.
OPRF's Isaiah Barnes averaged 20.3 PPG while his teammate Josh Smith averaged 19.8 PPG.
While it didn't place as high as it hoped, the team gained meaningful big-moment experience—something the youth on this squad lacked before Pontiac.
"I think we have shown flashes of what we could be," said OPRF coach Matt Maloney. "With our inexperience, I really believe this tournament is going to give us some fuel going into the second half and be a coming of age experience for a lot of our players."
Here is a day-by-day overview about what went down at the tournament.
Day one: Huskies stifle Plainfield North's comeback
After allowing 31 points in the first three quarters against Plainfield North High School, the Huskies surrendered 32 points in the fourth quarter and lost their 14-point lead.
They avoided the upset after Justin Cross hit converted a three-point play with 34 seconds left to put OPRF up by one. Rashad Trice followed Cross' 3-point play with a layup with 13.4 seconds left to secure the victory.
Josh Smith led the Huskies with 22 points, 7 rebounds, and 5 assists. Cross brought his consistent play to Pontiac and provided his team with 13 points, 10 rebounds and 2 steals. Isaiah Barnes had 14 points on 5-of-13 shooting.
"We lost our composure a little bit," said Smith on a phone call with Wednesday Journal on Dec. 26. "A win is a win, but we can't put ourselves in a situation like that again. We can't come out like we did in the fourth quarter when we face Bloom tomorrow or else we aren't going to be in the game. We made some key plays at the end but we should have never lost that lead."
Day two: Huskies fall to Bloom
Riding a four-game win streak heading into the second round of the tournament, OPRF held a 15-13 lead after the first quarter against No. 1 seeded Bloom High School. However, the Huskies couldn't build off their first quarter efforts and ended up surrendering their lead and 51 points in the second half.
OPRF's Josh Smith racked up 16 points (4-of-15 from the field) while his teammate Isaiah Barnes went for 15 points (4-of-10). Bloom's Dante Maddox Jr. had himself a day with 30 points and 6 rebounds. Three other Bloom players scored in double-figures.
This was the second year in a row that the Huskies lost to Bloom in the second round of the Pontiac tournament.
Day three: Huskies split double-header
The Huskies journey for sixth place started at 9:30 a.m. on Dec. 28 versus Warren Township when they took down the Blue Devils 63-53. After scoring only two points in the first quarter, OPRF outscored Warren Township 61-40 the rest of the way.
Smith had 25 points (9-of-14 shooting) and grabbed 4 rebounds. Cross put up 7 points, 8 rebounds, and 4 assists while Barnes had 12 points (4-of-12), 3 rebounds, and 3 assists.
OPRF followed their morning matchup against Warren Township with an evening game against Simeon. Down 20, the Huskies were able to erase Simeon's lead to three with less than a minute left before losing 80-74.
Barnes went for 27 points (7-of-20 shooting) and Smith had 16 points (5-of-19).
"Watching the growth of Isaiah Barnes was truly tremendous," said Maloney. "[Against Simeon], he had such an unbelievable performance against Ahmad Bynum, who is committed to DePaul, and there were times where he put us on his back and carried us offensively."
Barnes picked up on what Simeon was trying to throw at him and took advantage of the mismatches.
"I was able to get to the rim any time I wanted," said Barnes who went 10 of 11 at the free throw line. "Coach Maloney realized that and he kept running a 1-4 low so I was driving and kicking and driving and getting fouled. Everything was just flowing for me and we found ourselves back in the game."
The Huskies return to action in 2020 against Glenbard West on Jan. 10 at home. Heading into the new year, OPRF is still making small adjustments and trying to find consistency through all 32 minutes of the game.
However, Barnes takes the long view with how this younger team will look come playoff time.
"The losses we took are all lessons," said Barnes on a phone call with Wednesday Journal on Dec. 28. "The season goes by fast but it is only December. Coach [Maloney] keeps telling us that he loves how we never quit and how we will look like a different team in February and March when it really matters."
Love the Journal?
Thanks for turning to Wednesday Journal and OakPark.com. We love our thousands of digital-only readers. Now though we're asking you to partner up in paying for our reporters and photographers who report this news. It had to happen, right?


text:
Clothing, adornment and images
Having a relaxed attitude towards wearing Islamic dress in front of non-mahrams
What is the Islamic ruling on a woman whose attitude towards wearing Islamic dress is too relaxed and who sits with her brother in law?
The Qur'aan and Sunnah both direct women to cover themselves and avoid displaying their adornments in front of "strangers" (non-mahram men). The Qur'aan tells the Prophet (peace and blessings of Allaah be upon him) (interpretation of the meaning):
"O Prophet! Tell your wives and your daughters and the women of the believers to draw their cloaks (veils) all over their bodies (i.e. screen themselves completely except the eyes or one eye to see the way). That will be better, that they should be known (as free respectable women) so as not to be annoyed. And Allâh is Ever Oft-Forgiving, Most Merciful" [al-Ahzaab 33:59].
Allaah commanded His Prophet (peace and blessings of Allaah be upon him) to start by telling his wives and daughters to wear the jilbaab (i.e., the abaayah or an outer garment), because he and his family are examples for the believing men and women, then he was to command the believing women to do likewise:
"That will be better, that they should be known (as free respectable women) so as not to be annoyed" means, if a woman wears the jilbaab, it will be known that she is a decent woman who covers herself and desires chastity, unlike the women of the Jaahiliyyah who uncovered their adornments and temptations in front of all men, so she herself would be tempted and she would tempt others, she was misled and she misled others, as the Prophet (peace and blessings of Allaah be upon him) described them in the hadeeth narrated by Muslim:
"There are two types of the people of Hell whom I have not seen: men with whips like the tails of cattle with which they strike the people, and women who are clothed but naked, walking with an enticing gait, with something like the humps of camels on their heads. They will not enter Paradise nor even smell its fragrance, and its fragrance can be smelled from such and such a distance."
The Messenger (peace and blessings of Allaah be upon him) also warned against having too relaxed an attitude towards the matter of women mixing with men who are not her mahrams, or who are only temporarily her mahrams, like her sister's husband or her husband's brother and so on. He (peace and blessings of Allaah be upon him) said: "Beware of entering upon women." They said, "O Messenger of Allaah, what do you think about the brother-in-law?" he said: "The brother in law is death." I.e., many people have a relaxed attitude towards the brother-in-law entering upon women, until some disaster happens as a result, that they never thought would happen because they trusted their brother-in-law! This is neglecting reality, because no man is alone with a (non-mahram) woman but the Shaytaan is the third one present with them, and no woman is exposed to temptation but she will give in, except for those on whom Allaah has mercy. We ask Allaah to keep us all safe from that, and to help us follow His words (interpretation of the meaning):
"And all of you beg Allaah to forgive you all, O believers, that you may be successful" [al-Noor 24:31]
Source: Masaa'il wa Rasaa'il, Muhammad al-Mahmood al-Najdi, p. 11


text:
Q: how to prove $\int_{0}^{1} \frac{1-\cos x}{x^{n}}$ converges only for $n < 3$ how to prove $\int_{0}^{1} \frac{1-\cos x}{x^{n}}$ converges only for $n < 3$
I am stuck here :
$\int_{0}^{1} \frac{1-\cos x}{x^{n}} = \frac{x-\sin x}{x^n}\bigg\rvert_0^1-n\int_{0}^{1} \frac{\sin x}{x^n+1}$

A: $f: x\mapsto \frac{1-\cos(x)}{x^n}$ is continuous and positive at $(0,1]$.
on the other hand, near zero,
$$1-\cos(x)=2\sin^2(\frac x2)\sim \frac{x^2}{2}$$
thus
$$f(x)\sim \frac{1}{2x^{n-2}}\;\; (x\to 0^+)$$
hence the integral converges only if
$$n-2<1.$$

A: Near $0$; $1-\cos(x)$ behaves as $\frac12x^2$. Therefore, $\frac{1-\cos(x)}{x^n}$ behaves as $\frac12x^{2-n}$ and this explains whay your integral converges if an only if $n<3$.

A: $1-cos(x)=-\sum_{k=1}^\infty(-1)^k\frac{x^{2k}}{(2k)!}$. We can use this to keep things bounded for $n<3$,
$$
\frac{1-cos(x)}{x^n}=-\sum_{k=1}^\infty(-1)^k\frac{x^{2k-n}}{(2k)!}
$$
Indeed, the above is bounded as long as $2-n\geq 0$, or $n$, an integer, is $n\leq 3$.
For $n>3$, you have something at least as bad as $1/x$ you are trying to integrate near 0.

redpajama_set_name: RedPajamaStackExchange


text:
Unilever to remove 'normal' from packaging, ads of beauty & personal care brands
By GraniaJain on Wed, 03/10/2021 - 17:22
Consumer goods giant Unilever on Tuesday said it is set to remove the word "normal" from the packaging and advertising of all its beauty and personal care brands, to make its campaigns more inclusive. The company also plans to stop digitally altering a person's body shape and skin colour in its commercials as it moves to a more equitable idea of promoting beauty products.
The move comes as consumers the world over seek greater inclusivity from the brands they purchase.
The Positive Beauty vision and strategy will extend to Unilever's beauty and personal care brands, including Dove, Lifebuoy, Axe and Sunsilk, in markets such as India, Unilever said. Apart from promoting an equitable idea of beauty, it will expand sustainable goals set by the company.
Unilever added that it will also increase the number of advertisements portraying people from diverse and under-represented groups. It will work towards ending discrimination in beauty and champion inclusion, drive gender equality and expand the sustainability agenda of its beauty and personal care products, it said.
"The decision to remove "normal" is one of the many steps that we are taking to challenge narrow beauty ideals, as we work towards helping end discrimination and advocating for a more inclusive vision of beauty. It comes as global research into people's experiences of the beauty industry reveals that using "normal" to describe hair or skin makes most people feel excluded," the company said in a statement.
In India, Hindustan Unilever Ltd has announced a series of changes to its key brands and tweaked marketing campaigns that promote socially accepted beauty ideals—it changed the name of its flagship Fair & Lovely beauty brand to Glow & Lovely.
More recently, its brand, Dove, partnered with matrimonial platforms to drop the usage of words such as fair and tall from match-making advertisements.
Unilever said the project will also drive a transformation in how its products are designed and formulated so that they do better for both people and the planet.
In India, Hindustan Unilever Ltd., also undertook research to understand consumer perception and expectations from beauty brands.
Almost two in three people in India agree that the beauty and personal care industry makes certain people feel excluded. Six in ten of those surveyed here said the beauty industry makes certain people feel bad about the way they look. Indian consumers also said that the beauty industry perpetuates narrow beauty ideals; two in three think that the industry pressures consumers into thinking they need to look a certain way.
Indian companies have for years sold fairness or skin lightening creams often with promises of improving one's job and marriage prospects through their advertisements.
When it comes to representation, most Indian consumers agree that the beauty and personal care industry lags when it comes to representing various body types, people from different age groups, different ethnicities and those from the LGBTQIA community.
Consumers in India are also paying more attention to a company's overall stance on societal issues before they buy products. Six in ten people here said they will not buy a product if they do not agree with the company's vision of diversity and inclusion, even if the company offers the best price.


Le Bon Coin Auto Rhone Alpes Le Bon Coin Immo Rhone Alpes Frais Schibsted Second Hand Effect is a part of Imposant Le Bon Coin Auto Rhone Alpes pictures gallery. To download this (Le Bon Coin Auto Rhone Alpes Le Bon Coin Immo Rhone Alpes Frais Schibsted Second Hand Effect) in High Resolution, right click on the image and choose "Save Image As" and then you will get this image about Le Bon Coin Auto Rhone Alpes Le Bon Coin Immo Rhone Alpes Frais Schibsted Second Hand Effect.
This digital photography of Le Bon Coin Auto Rhone Alpes Le Bon Coin Immo Rhone Alpes Frais Schibsted Second Hand Effect has picture size 2048x1536 pixels. You can see another items of this gallery of Imposant Le Bon Coin Auto Rhone Alpes below. Get interesting article about Imposant Le Bon Coin Auto Rhone Alpes that may help you. Admin, Regards.


Now's the time to schedule the Vikings for your Spring projects! Every year we hire more staff and every year we gain more satisfied customers.
Once again the Vikings have won the Angie's List SUPER SERVICE AWARD! In earning this great honor, we provided MORE SERVICES to MORE CUSTOMERS in 2017 than any other year in our history!
In 2017, the Vikings cleaned 218,942 windows, power washed 361,214 square feet, and cleared 230,759 linear feet of gutters!
WINDOW CLEANING IN ROCKFORD AND THE STATELINE AREA.
At CARLSON, service is our business. It's what we do (and we do a lot of it) and we're really good at it.
We're a local, family-owned and operated company - always have been, always will be.
No job is too big or too small. Hiring a professional is actually an incredibly economical idea. We're able to get done twice as much in half the time, which means it would take you four times as long as it takes us! Give us a call today and see what a difference we can make for you.
"Serving to Make Life Better!"
At the Carlson Company, since 1924, some things don't change, like Integrity, Excellence, Professionalism, and Communication.
Hire the Vikings, the experts with Superior Service!
Storefront Windows cleaned at the lowest price! Call for a quote 815-847-6690.
Serving the Chicago Suburbs, Madison, Milwaukee, Rockford, Northern Illinois, and Southern Wisconsin.


Can you please suggest me which company provide mice control services?
Actually, the reason is that this service needs for my house & mice create a problem in our house because of my house member tired to kill mice so, please suggest the company with services details.
Check your local area for Pest control companies. They would be best for handling the pesky rodent situation.
Or get a couple of cats and don't declaw them.


The Grip Solid golf training aid is a thin rubber strap, which uses innovative 3D FLEX•BAR technology to solve grip pressure and position problems.
Raised soft ergonomic FLEX•BAR fins on palm side contour against your club grip, working intuitively to eliminate "death grips" and help you achieve greater distance and accuracy each time you swing.
Grip Solid is the only golf training device that instantly lets you know when you're gripping too tight! Order your Grip Solid now and start playing better golf immediately.
If you have any questions regarding the Grip Solid Golf Grip Training Aid, please give us a call, we would be happy to help you with any questions you may have.
Write an online review on the Grip Solid Golf Grip Training Aid, and share your thoughts with others.


Our mission is to develop regionally-specific, climate appropriate building technologies for neighborhoods of Allegheny County. The focus is on the implementation of strategies which can be replicated within the dominant social, political and economic realities of the area. Development of these strategies is dependent upon involvement of these communities in a participatory process to understand existing conditions and the realities of the site. Through partnership and design charettes we intend to encourage the development of the region's housing stock and creative potential.
Since 2008, the UDBS has worked on real projects, bringing university students off campus to be inspired by people who are actively advocating for their communities. Students gain valuable experience working with a local client, detailing their designs through construction documents, and full-scale prototyping before participating in final construction. The UDBS is dedicated to producing positive architectural solutions for communities in need, while also providing architecture students with extensive skills to enter the complex realm of architectural practice.
Each year, 4th- and 5th-year undergraduate and graduate architecture students participate in design, project management and construction. Project development is dependent on the engagement of communities, clients, and stakeholders to help students understand existing neighborhood conditions and future aspirations. The process is predicated on collective intelligence, is highly collaborative, and involves hands on making as an essential design tool. Our goal is to develop regionally-specific, appropriate, affordable, and replicable projects for traditionally under-served Pittsburgh area clients.